Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $127.65 million. The enterprise value is -$25.19 million.
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.25 million shares outstanding. The number of shares has increased by 0.51% in one year.
| Current Share Class | 10.25M |
| Shares Outstanding | 10.25M |
| Shares Change (YoY) | +0.51% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 69.50% |
| Float | 8.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| Forward PS | 0.48 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 34.34 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.80, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.80 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 15.86 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -9.80% and return on invested capital (ROIC) is -42.28%.
| Return on Equity (ROE) | -9.80% |
| Return on Assets (ROA) | -4.33% |
| Return on Invested Capital (ROIC) | -42.28% |
| Return on Capital Employed (ROCE) | -8.78% |
| Weighted Average Cost of Capital (WACC) | 6.56% |
| Revenue Per Employee | $910,800 |
| Profits Per Employee | -$52,689 |
| Employee Count | 380 |
| Asset Turnover | 1.30 |
| Inventory Turnover | 3.40 |
Taxes
In the past 12 months, Medifast has paid $11.92 million in taxes.
| Income Tax | 11.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.01% in the last 52 weeks. The beta is 0.57, so Medifast's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -11.01% |
| 50-Day Moving Average | 10.83 |
| 200-Day Moving Average | 11.86 |
| Relative Strength Index (RSI) | 64.09 |
| Average Volume (20 Days) | 193,075 |
Short Selling Information
The latest short interest is 2.03 million, so 19.82% of the outstanding shares have been sold short.
| Short Interest | 2.03M |
| Short Previous Month | 2.06M |
| Short % of Shares Out | 19.82% |
| Short % of Float | 24.15% |
| Short Ratio (days to cover) | 10.51 |
Income Statement
In the last 12 months, Medifast had revenue of $346.10 million and -$20.02 million in losses. Loss per share was -$1.82.
| Revenue | 346.10M |
| Gross Profit | 242.70M |
| Operating Income | -18.43M |
| Pretax Income | -8.11M |
| Net Income | -20.02M |
| EBITDA | -3.99M |
| EBIT | -18.43M |
| Loss Per Share | -$1.82 |
Full Income StatementBalance Sheet
The company has $168.95 million in cash and $16.10 million in debt, with a net cash position of $152.85 million or $14.91 per share.
| Cash & Cash Equivalents | 168.95M |
| Total Debt | 16.10M |
| Net Cash | 152.85M |
| Net Cash Per Share | $14.91 |
| Equity (Book Value) | 197.68M |
| Book Value Per Share | 19.28 |
| Working Capital | 160.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $3.72 million and capital expenditures -$5.19 million, giving a free cash flow of -$1.47 million.
| Operating Cash Flow | 3.72M |
| Capital Expenditures | -5.19M |
| Depreciation & Amortization | 14.45M |
| Net Borrowing | n/a |
| Free Cash Flow | -1.47M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
Gross margin is 70.12%, with operating and profit margins of -5.32% and -5.78%.
| Gross Margin | 70.12% |
| Operating Margin | -5.32% |
| Pretax Margin | -2.34% |
| Profit Margin | -5.78% |
| EBITDA Margin | -1.15% |
| EBIT Margin | -5.32% |
| FCF Margin | n/a |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.51% |
| Shareholder Yield | -0.51% |
| Earnings Yield | -15.68% |
| FCF Yield | -1.15% |
Dividend DetailsAnalyst Forecast
The average price target for Medifast is $12.00, which is -3.61% lower than the current price. The consensus rating is "Hold".
| Price Target | $12.00 |
| Price Target Difference | -3.61% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 4.19 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 3 |
